Pfizer Raises Forecast on Momentum With New Products — Update

What happened

Pfizer raised its full-year forecast, projecting sales of $62 billion to $64 billion, up from $60.5 billion to $62.5 billion. It now expects adjusted earnings per share of $2.95 to $3.05, compared with a prior range of $2.80 to $3. New products gained 32% in the latest quarter.

Confirmed

Global impact / market context

The raised forecast signals Pfizer is replacing falling Covid product revenue with new medicines and acquisitions. Higher sales guidance means more cash coming in, which supports research spending and dividends. Investors see whether that replacement strategy can keep profit growing after the pandemic surge fades.

Analyst inference

Pfizer faces shrinking demand for Covid vaccines and treatments, so growth now depends on cancer drugs and other new products. Its updated earnings range brackets the $2.96 average analyst estimate, suggesting the raise was largely expected. Rival drugmakers face similar pressure to refill product pipelines.

Analyst inference

What to watch

1. Watch whether sales of new products like Padcev and Lorbrena keep growing fast enough to offset further declines in Covid products Comirnaty and Paxlovid. Confirmed
2. Pfizer could pursue more acquisitions, including weight-loss drugs, to strengthen its pipeline, which would use cash and affect future research spending. Proposed
3. If new-product sales slow or Covid declines accelerate, Pfizer may need to cut costs or lower guidance again, pressuring the stock price. Analyst inference

Evidence

• Original source link unavailable